In NYC Subway, CyberKnife Prostate Cancer Ads Mislead

Survey Respondents Influenced by Claims

Direct-to-consumer (DTC) advertising about the radiotherapy (RT) known as CyberKnife (CK), which is currently omnipresent in the New York City transit system, creates “inaccurate impressions” about the treatment’s “comparative effectiveness and safety” in prostate cancer, according to new research.

That conclusion was made by investigators from Columbia University Medical Center after they created an online survey involving 400 men that used language lifted directly from an advertisement. The investigators compared the participants’ responses to the CyberKnife advertisement to responses to information about other prostate cancer treatments.

The results may surprise you. Read about the findings here.

This entry was posted in News. Bookmark the permalink.